Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT05087524 Terminated - COVID-19 Clinical Trials

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

Start date: January 9, 2021
Phase: N/A
Study type: Interventional

This is a study of the BinaxNOW Covid-19 Ag Card as a method to rapidly identify SARS-CoV-2 infection in asymptomatic children, teachers, and other school staff for exclusion. 240 students and 80 teachers in the Madison Metropolitan School District (MMSD) will be enrolled and can expect to be on study for up to 8 weeks.

NCT ID: NCT05084755 Terminated - Clinical trials for Prevention of Infectious Disease Caused by SARS-CoV-2

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

Start date: November 11, 2021
Phase:
Study type: Observational

To provide more information on safety profile of VAXZEVRIA in Japanese subjects, specific drug use result study in subjects with underling disease at higher risk of worsening COVID-19 is planned as an additional pharmacovigilance plan. The present study aims to collect information on adverse drug reactions or COVID-19 infection after VAXZEVRIA vaccination and to evaluate the safety of this vaccine.

NCT ID: NCT05077969 Terminated - COVID-19 Clinical Trials

Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2)

Start date: December 29, 2021
Phase: Phase 2
Study type: Interventional

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib. Each of these agents separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and each of which appear to have separate and complementary mechanisms of action.

NCT ID: NCT05037188 Terminated - COVID-19 Clinical Trials

Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

COVER
Start date: August 10, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled, adaptive, seamless phase I / II clinical study of the safety and immunogenicity of a recombinant viral vector AAV5-RBD-S vaccine for the prevention of coronavirus infection (COVID-19)

NCT ID: NCT05032625 Terminated - Clinical trials for Necrotizing Soft Tissue Infection

To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections

Start date: July 1, 2019
Phase:
Study type: Observational

There is significant mortality associated with necrotizing soft tissue infections, it is imperative to decrease mortality and complications associated with this disease is determined. To accomplish this goal, study team will create a prospectively maintained database of all NSTI patients admitted at department of surgery. Investigators will asses the predictors of poor outcome and follow these patients for 1 year in clinic and asses the functional quality of life by incorporating 36-Item Short Form Survey (SF-36) score.

NCT ID: NCT05014516 Terminated - Clinical trials for COVID-19 Respiratory Infection

Lung Structure-Function In SurVivors of Mild and SEvere COVID-19 Infection: 129Xe MRI

LivCovidFree
Start date: August 5, 2021
Phase:
Study type: Observational

In this study the Investigators aim to deploy UTE and HP 129Xe MRI for structural and functional evaluation of persistent lung abnormalities in COVID-19 survivors.

NCT ID: NCT04971512 Terminated - Clinical trials for Chronic Hepatitis B Virus Infection

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Start date: August 2, 2021
Phase: Phase 1
Study type: Interventional

Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EDP-721 in healthy subjects. Part 2 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of EDP-721 in combination with EDP-514 in patients with chronic hepatitis B virus infection.

NCT ID: NCT04933968 Terminated - Influenza Infection Clinical Trials

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

Start date: March 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A study to evaluate ALVR106; an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets four community acquired respiratory viruses: respiratory syncytial virus (RSV), influenza, human metapneumovirus (hMPV), and/or parainfluenza virus (PIV) following hematopoietic cell transplant (HCT) and solid organ transplant (SOT).

NCT ID: NCT04912180 Terminated - Influenza Clinical Trials

Apple Respiratory Study

ARS
Start date: April 6, 2021
Phase:
Study type: Observational

The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective, longitudinal cohort, low risk Study to collect certain data from Apple Watch and iPhone to determine whether such data can detect physiologic and non-physiologic changes in individuals associated with respiratory illnesses due to influenza, SARS-CoV-2 and other respiratory pathogens (the "Study").

NCT ID: NCT04906512 Terminated - Clinical trials for Catheter-Related Infections

Comparing CHG I.V. Securement Dressing With Transparent Dressing for Evaluation of Antimicrobial Efficacy

Start date: May 14, 2021
Phase: N/A
Study type: Interventional

This is a single-center, prospective, randomized controlled clinical trial designed to compare the antimicrobial efficacy of Tegaderm CHG I.V. Securement Dressing and transparent dressings for deep vein catheterization in adult ICU patients.